<DOC>
	<DOCNO>NCT00080925</DOCNO>
	<brief_summary>RATIONALE : Donor peripheral stem cell transplantation may able replace bone marrow immune cell destroy chemotherapy . Sometimes transplanted cell donor reject body 's normal cell . Eliminating T cell donor cell transplant give cyclosporine may prevent happen . PURPOSE : This phase I trial study side effect T-cell-depleted allogeneic stem cell transplantation immunoablative induction chemotherapy reduced-intensity transplantation conditioning ( chemotherapy ) treat patient hematologic malignancy .</brief_summary>
	<brief_title>T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy Reduced-Intensity Transplantation Conditioning Treating Patients With Hematologic Malignancies</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine engraftment patient hematologic malignancy treat T-cell-depleted allogeneic stem cell transplantation immunoablative induction chemotherapy reduced-intensity transplantation conditioning . Secondary - Determine incidence acute graft-versus-host disease ( GVHD ) , nonrelapse mortality ( within 100 day transplantation ) patient . - Correlate level host immunosuppression transplantation conditioning , evaluate peripheral blood CD4 count , graft rejection/failure within 100 day transplantation level donor hematopoietic chimerism 28 day transplantation patient . - Correlate donor-versus-recipient natural killer cell alloreactivity graft rejection/failure , acute GVHD , relapse malignant disease patient treat regimen . - Determine development allospecific cytotoxic T-lymphocytes transplantation patient myeloid lymphoid leukemia . - Correlate serum interleukin-7 interleukin-15 level vivo change host lymphocyte subpopulation patient sequential immunoablative chemotherapy , allogeneic stem cell transplantation , immune reconstitution transplantation . OUTLINE : This pilot study . - Induction chemotherapy : Patients receive 1 2 induction chemotherapy regimens accord diagnosis . Patients partial response well prior therapy ( i.e. , already adequately immune deplete ) proceed directly transplantation preparative regimen . - Regimen A ( Hodgkin 's lymphoma , non-Hodgkin 's lymphoma [ except lymphoblastic lymphoma ] , chronic lymphocytic leukemia , prolymphocytic leukemia , multiple myeloma ) : Patients receive rituximab IV ( CD20+ B-cell malignancy ) day 1 ; fludarabine IV 30 minute day 1-4 ; etoposide , doxorubicin , vincristine IV continuously day 1-4 ; cyclophosphamide IV 30 minute day 5 ; oral prednisone day 1-5 ; filgrastim ( G-CSF ) subcutaneously ( SC ) begin day 6 continue blood count recover . - Regimen B ( lymphoblastic lymphoma , acute myeloid leukemia , acute lymphoblastic leukemia , refractory anemia excess blast , myeloproliferative disorder , chronic myelomonocytic leukemia , chronic myelogenous leukemia ) : Patients receive G-CSF SC begin 24 hour initiate induction chemotherapy continue blood count recover . Patients also receive fludarabine IV 30 minute cytarabine IV 4 hour day 1-5 . For regimen , treatment repeat every 21 day 1-2 course . Patients achieve remission responsive stable disease induction chemotherapy proceed transplantation preparative regimen chemotherapy . - Transplantation preparative regimen chemotherapy : Patients receive fludarabine IV 30 minute cyclophosphamide IV 2 hour day -6 -3 . - Graft-versus-host disease ( GVHD ) prophylaxis : Patients receive cyclosporine IV 2 hour twice daily begin day -1 continue IV orally day 100 . Patients acute GVHD day 100 taper cyclosporine 12 week . - Allogeneic stem cell transplantation ( SCT ) : Patients undergo T-cell-depleted allogeneic peripheral blood SCT day 0 . Patients receive G-CSF SC begin day 0 continue blood count recover . - Donor lymphocyte infusion ( DLI ) : Patients persistent progressive malignant disease transplantation mixed chimerism improve taper discontinue immunosuppression therapy may receive DLI . DLI may administer alone combination chemotherapy . DLI repeat every 4 week adequate donor chimerism achieve GVHD develops . Patients follow 28 100 day 6 , 9 , 12 , 18 , 24 month . PROJECTED ACCRUAL : A total 6-20 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 follow hematologic malignancy : Acute myeloid leukemia ( AML ) , meet 1 follow criterion : In first complete remission ( CR1 ) , meet 1 follow criterion : Adverse cytogenetics minimal residual disease detectable flow cytometry , cytogenetic analysis , fluorescence situ hybridization ( FISH ) , polymerase chain reaction ( PCR ) , define 1 following : Complex karyotype [ ≥ 3 abnormality ] inv ( 3 ) ( 3 ; 3 ) ( 6 ; 9 ) ( 6 ; 11 ) Monosomy 7 Trisomy 8 , alone abnormality ( 8 ; 21 ) , ( 9 ; 11 ) , inv ( 16 ) , ( 16 ; 16 ) ( 11 ; 19 ) ( q23 ; p13.1 ) Failed achieve CR primary induction chemotherapy Secondary AML In second subsequent remission ( CR2 great ) Acute lymphoblastic leukemia , meet 1 follow criterion : In CR1 , meet 1 follow criterion : Adverse cytogenetics minimal residual disease detectable flow cytometry , cytogenetic analysis , FISH , PCR , define follow : Translocations involve 11q23 , ( 9 ; 22 ) , bcrabl rearrangement Failed achieve CR primary induction chemotherapy In CR2 , CR1 &lt; 12 month In CR3 great Myelodysplastic syndrome ( MDS ) INT2 highrisk International Prognostic Scoring System No MDS Fanconi anemia Chronic myelogenous leukemia ( CML ) , meet 1 follow criterion : Accelerated phase treatment failure imatinib mesylate Blast phase Myeloproliferative disorder , meet 1 follow criterion : Agnogenic myeloid metaplasia adverserisk feature , meet least 2 follow criterion : Hemoglobin &lt; 10 g/dL &gt; 10g/dL transfusiondependent WBC &lt; 4,000/mm^3 OR &gt; 30,000/mm^3 OR require cytoreductive therapy maintain WBC &lt; 30,000/mm^3 Abnormal cytogenetics , include +8 , 12p Polycythemia vera essential thrombocythemia transformation secondary AML Myelodysplastic/myeloproliferative disease Chronic myelomonocytic leukemia Hodgkin 's lymphoma nonHodgkin 's lymphoma Refractory lymphoma progressive disease combination chemotherapy Relapse OR ineligible autologous stem cell transplantation ( SCT ) Chronic lymphocytic leukemia Treatment failure* fludarabine , chlorambucil , least 1 salvage regimen Prolymphocytic leukemia ( PLL ) , meet 1 follow criterion : TPLL Treatment failure* alemtuzumab least 1 regimen BPLL Treatment failure* fludarabine least 1 salvage regimen Multiple myeloma , meet 1 follow criterion : Relapse autologous SCT Plasma cell leukemia Adverse cytogenetics , define 1 following : del ( 13q ) = 11q translocation NOTE : *Treatment failure define relapse within 6 month OR failure achieve remission Less 10 % blast bone marrow circulate blast peripheral blood follow diagnosis : Primary secondary leukemia Refractory anemia excess blast CML Other eligible diagnosis transformation acute leukemia Expected survival approximately 1 year less conventional therapy No active CNS involvement malignancy* Prior CNS involvement current evidence CNS malignancy allow NOTE : *Active CNS malignancy define lymphoma : tumor mass CT scan leptomeningeal disease OR leukemia : blast present cerebrospinal fluid cytospin Availability donor sibling , parent , offspring share 1 full haplotype ( HLAA , B , DR ) Recipient donor must least 2antigen disparity either hostversusgraft graftversushost direction Parent offspring donor mismatch single HLA antigen ( i.e. , 5/6 HLA ) allow No sibling donor 6/6 HLAmatched OR mismatch single HLA antigen ( i.e. , 5/6 HLA ) No unrelated donor identify prior current National Marrow Donor Program registry search PATIENT CHARACTERISTICS : Age 18 55 Performance status ECOG 02 OR Karnofsky 60100 % Life expectancy At least 3 month Hematopoietic See Disease Characteristics Absolute neutrophil count ≥ 1,000/mm^3* Platelet count ≥ 20,0000/mm^3* ( without transfusion ) NOTE : *Lower value may accept discretion principal investigator study chairperson due bone marrow involvement malignancy Hepatic ALT AST ≤ 2.5 time upper limit normal ( ULN ) * Bilirubin ≤ 2.5 time ULN* Unconjugated hyperbilirubinemia consistent Gilbert 's syndrome allow No chronic active hepatitis B infection Hepatitis B core antibody positive allow provided patient surface antigen negative evidence active infection No hepatitis C viral infection Seronegative antihepatitis C antibody detectable hepatitis C viral RNA reverse transcriptasepolymerase chain reaction assay NOTE : *Higher level may accept discretion principle investigator study chairperson elevation due liver involvement malignancy Renal Creatinine ≤ 1.5 mg/dL OR Creatinine clearance ≥ 50 mL/min Cardiovascular LVEF ≥ 45 % Pulmonary DLCO ≥ 50 % expect value ( correct blood hemoglobin level alveolar volume ) Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 year study participation HIV negative No active infection respond antimicrobial therapy No psychiatric disorder would preclude study compliance inform consent PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics At least 2 week since prior monoclonal antibody therapy Chemotherapy See Disease Characteristics At least 2 week since prior systemic chemotherapy Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other Recovered prior therapy No administration tyrosine kinase ( TK ) inhibitor , include imatinib mesylate dasatinib , condition regimen ; TK inhibitor administration may resume 28 day transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
</DOC>